Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RXI-231
- Development stage
- Preclinical
- Lead developer
- Phio Pharmaceuticals
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Topical
01
Overview
RXI-231 is a self-delivering RNA interference (RNAi) compound developed using Phio Pharmaceuticals' proprietary INTASYL siRNA gene silencing technology. It is designed to target and reduce the expression of the tyrosinase (TYR) gene, a key enzyme involved in melanin synthesis. By downregulating TYR, RXI-231 reduces melanin production and pigmentation in skin cells. Preclinical studies have shown that topical application of RXI-231 significantly decreases tyrosinase mRNA levels and melanin content in both normal human melanocytes and 3D human epidermal models. The compound has demonstrated visible reduction of pigmentation without causing skin irritation, supporting its potential as a treatment for hyperpigmentation disorders such as melasma and lentigines. Further clinical characterization is ongoing[1][2][3][5][6].
- Other names
- INTASYL RXI-231sd-rxRNA targeting tyrosinase
02
Targets
TYR (Tyrosinase)
Beyond the preview
Go deeper on RXI-231.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RXI-231.